With this trial we would like to further evaluate the safety, tolerability and efficacy of the trial medication BAY-1895344 in combination with Pembrolizumab in patients with advanced cancer (certain types of solid malignant tumors). This combination therapy with Pembrolizumab is being tested in humans for the first time.

Patients, who are suffering from a malignant solid tumor and where standard treatments are no longer working, can participate. In addition, a certain type of gene deficiency/mutation must be present in these patient populations. Up to 160 patients worldwide will take part.

For more information on where and how this trial is conducted, consult the trial website.